Locations:
SearchLong-term follow-up results of ZUMA-1, a trial examining anti-CD19 CAR T cell therapy in non-Hodgkin lymphoma, show significant clinical benefit in patients with no curative treatment options, according to a study presented at ASH 2017 and published December 2017 in New England Journal of Medicine. Brian T. Hill, MD, PhD, staff in Cleveland Clinic Cancer Center’s Department of Hematology and Medical Oncology, is a coauthor.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Watch Dr. Hill discuss the study design and results below:
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy